Myositis/Myasthenia after Pembrolizumab in a Bladder Cancer Patient with an Autoimmunity-Associated HLA: Immune–Biological Evaluation and Case Report

Pembrolizumab (mAb to PD-1) has been recently approved for the therapy of pretreated urothelial cancer. Despite the efficacy, it is often accompanied by unpredictable and sometime severe immune-related (ir) adverse events (AEs). Here, we report the clinical and immune–biological characterization of...

Descripción completa

Detalles Bibliográficos
Autores principales: Botta, Cirino, Agostino, Rita Maria, Dattola, Vincenzo, Cianci, Vittoria, Calandruccio, Natale Daniele, Bianco, Giovanna, Mafodda, Antonino, Maisano, Roberto, Iuliano, Eleonora, Orizzonte, Giovanna, Mazzacuva, Domenico, Falzea, Antonia Consuelo, Saladino, Rita Emilena, Giannicola, Rocco, Restifo, Giorgio, Aguglia, Umberto, Caraglia, Michele, Correale, Pierpaolo
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2021
Materias:
Case Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8230397/
https://www.ncbi.nlm.nih.gov/pubmed/34200673
http://dx.doi.org/10.3390/ijms22126246

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8230397/
https://www.ncbi.nlm.nih.gov/pubmed/34200673
http://dx.doi.org/10.3390/ijms22126246

Ejemplares similares